For generations, the idea of vaccinating against cancer occupied the hopeful margins of medicine — theoretically sound, clinically elusive. A breakthrough in melanoma treatment has now moved that idea from the margins to the center, and analysts project the cancer vaccine market will grow at 36 percent annually through 2036. What is unfolding is not merely a commercial expansion but a quiet restructuring of how humanity understands and confronts one of its oldest adversaries.